A test highlighting value in personalized medicine is mentioned in a competitive market assessment involving Roche, Bio-Rad, and Charles River.
3 reports, 2 independent
Updated Jun 22
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A test highlighting value in personalized medicine is mentioned in a competitive market assessment involving Roche, Bio-Rad, and Charles River.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Hoffmann-La Roche
Swiss healthcare company
-
Bio-Rad Laboratories
American life science research firm
- Strategic acquisitions and product launches are driving growth for Bio-Rad Laboratories in the life science ddPCR and clinical diagnostics markets.
- Bio-Rad Laboratories is applying digital PCR technology through current partnerships, including Biodesix, Gencove, Insight Molecular, and Stilla Technologies.
-
Charles River Laboratories
major US biomedical company
Coverage
Newest first; wire copies grouped- fool.com
- Unknown outlet
- GlobeNewswireProteomic Biomarker Analytics Market Forecast Report 2025: Proteomics Steps Up Where Genomics Falls Short Explore the future of proteomics where new biomarkers are redefining disease, possibly outpac